We further demonstrated that aminooxyacetic acid (AOA) could impede the p53-72Pro/PSAT1 interaction and combinational use of AOA and regorafenib, an FDA-proved drug for HCC and colorectal cancer (CRC), showed an obvious synergistic effect on inhibiting tumor growth in patient-derived xenograft models. Here, TP53 is linked to colorectal carcinoma.